TB Alliance Collaborates with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China
Shots:
- Hongqi to get a license to commercialize pretomanid as part of the three-drug “BPaL” regimen to treat a highly drug-resistant form of tuberculosis in People’s Republic of China
- The collaboration is a part of TB Alliance’s global commercialization strategy for pretomanid- complementing its previous agreement with Mylan & Macleods to commercialize pretomanid as part of the BPaL regimen in other countries
- Pretomanid is an anti-tuberculosis therapy & a part of BPaL (bedaquiline- pretomanid and linezolid) regimen- studied in P-III Nix-TB study and has received FDA’s approval as a combination therapy in Aug’2019
Click here to read full press release/ article | Ref: TB Alliance | Image: TB Alliance
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com